Stay informed with the latest litigation news. Explore now

IP Verse

Novartis Pharma competitive analysis

Latest publications and patents of Novartis Pharma New

Explore the latest publications and patents granted to Novartis Pharma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 6, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Novartis Pharma

EP4218732
Mar 26, 2025Tablets Comprising Eltrombopag OlamineGranted And Under Opposition
EP3143995
Jan 15, 2025A Rapamycin Derivative For Treating Lung CancerPatent Maintained As Amended
EP3090730
Jul 3, 2024Novel Pharmaceutical CompositionGranted And Under Opposition
EP2784084
Oct 4, 2023Il-17 A/F Heterologous Polypeptides And Therapeutics Uses ThereofPatent Maintained As Amended
EP3345602
Apr 6, 2022Rapamycin Derivative For Treating Advanced Solid TumoursGranted And Under Opposition
EP3003316
Jul 22, 2020Combination Therapies For CancerRevoked
EP2340828
Jul 15, 2020Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep InhibitorGranted And Under Opposition
EP2228064
Dec 11, 2019Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor AgonistGranted And Under Opposition
EP3351246
Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisRevoked
EP3342411
Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerOpposition Rejected

Latest patents of Novartis Pharma opposed by its competitors

Explore Novartis Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4218732
Mar 26, 2025Tablets Comprising Eltrombopag Olamine1
EP3143995
Jan 15, 2025A Rapamycin Derivative For Treating Lung Cancer7
EP3090730
Jul 3, 2024Novel Pharmaceutical Composition7
EP2784084
Oct 4, 2023Il-17 A/F Heterologous Polypeptides And Therapeutics Uses Thereof5
EP3345602
Apr 6, 2022Rapamycin Derivative For Treating Advanced Solid Tumours3
EP3003316
Jul 22, 2020Combination Therapies For Cancer1
EP2340828
Jul 15, 2020Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor8
EP2228064
Dec 11, 2019Pharmaceutical Composition Containing Glycopyrrolate And A Beta2 Adrenoceptor Agonist10
EP3351246
Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis9
EP3342411
Aug 21, 2019Rapamycin Derivative For Treating Pancreas Cancer10

Latest PTAB cases involving Novartis Pharma New

Discover the latest PTAB cases involving Novartis Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 12, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Novartis Pharma

IPR2023-01347Aug 28, 2023NOVARTIS PHARMACEUTICALSTHE REGENTS OF THE UNIVERSITY OF MICHIGANTerminated-Adverse Judgment
IPR2023-01346Aug 28, 2023NOVARTIS PHARMACEUTICALSTHE REGENTS OF THE UNIVERSITY OF MICHIGANFinal Written Decision - Appealed
IPR2022-00886Apr 20, 2022NOVARTIS PHARMACEUTICALSSHILPA PHARMAFinal Written Decision - Appealed
IPR2022-00853Apr 12, 2022MILTENYI BIOMEDICINENOVARTIS PHARMAInstitution Denied
IPR2021-00816Apr 16, 2021REGENERON PHARMACEUTICALSNOVARTIS PHARMAFinal Written Decision
IPR2020-01263Aug 7, 2020BIOCON PHARMANOVARTIS PHARMACEUTICALSInstitution Denied
IPR2020-01318Jul 16, 2020REGENERON PHARMACEUTICALSNOVARTIS PHARMATerminated
IPR2020-01317Jul 16, 2020REGENERON PHARMACEUTICALSNOVARTIS PHARMAInstitution Denied
PGR2018-00069Jun 18, 2018NOVARTIS PHARMACEUTICALPLEXXIKONInstitution Denied
IPR2018-01287Jun 18, 2018NOVARTIS PHARMACEUTICALSPLEXXIKONInstitution Denied

Top competitors of Novartis Pharma

Top competitors of Novartis Pharma based on patent oppositions.